Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04323189 · ClinicalTrials.gov registry record · Phase 4
Effects of Sitagliptin in Individuals With Genetically Decreased DPP4
A Phase 4 study of Heart Failure and Type 2 Diabetes, sponsored by University of Pennsylvania.
- Active
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT04323189: Active Phase 4 study of Heart Failure and Type 2 Diabetes, sponsored by University of Pennsylvania.
NCT04323189 is a Phase 4 study of Heart Failure and Type 2 Diabetes that is active but no longer recruiting, run by University of Pennsylvania. The registered enrollment target is 20 participants, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04323189, a Phase 4 study of Heart Failure and Type 2 Diabetes, is active but no longer recruiting, sponsored by University of Pennsylvania.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a pilot clinical trial to test the hypothesis that during sitagliptin (DPP4 inhibitor), individuals heterozygous for DPP4 loss of function variants will have a reduction in DPP4 activity and antigen, lower glucose after a mixed meal, and higher levels of intact DPP4 substrates compared to during placebo and compared to matched controls.
Primary Outcome
DPP4 activity and antigen concentration
Conditions Studied
Interventions
- DRUG Placebo Oral Tablet
- DRUG Sitagliptin 100mg
Study Locations (1)
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2020-08-26 |
| Est. Completion | 2026-02-28 |
| Phase | Phase 4 |
What the registry record for NCT04323189 still lists
NCT04323189 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (99% lower).
The record links to 3 conditions, with Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which Placebo Oral Tablet is the first listed.
NCT04323189 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04323189 about?
NCT04323189 is a clinical study titled "Effects of Sitagliptin in Individuals With Genetically Decreased DPP4". This is a pilot clinical trial to test the hypothesis that during sitagliptin (DPP4 inhibitor), individuals heterozygous for DPP4 loss of function variants will have a reduction in DPP4 activity and antigen, lower glucose after a mixed meal, and higher levels of intact DPP4 substrates compared to du...
What is the current status of trial NCT04323189?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2020-08-26. Estimated completion is 2026-02-28.
What conditions does trial NCT04323189 study?
This clinical trial studies the following conditions: Heart Failure, Type 2 Diabetes, Genetics Disease.
What interventions are being tested in trial NCT04323189?
The interventions under investigation include: Placebo Oral Tablet (DRUG), Sitagliptin 100mg (DRUG).
Who is sponsoring clinical trial NCT04323189?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04323189 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04323189's enrollment target sits among peer trials
20 350th of 397 higher than 37 of 397 other Heart Failure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Gator SCALES-WHF: SubCutaneous Administration of Lasix to Eliminate Symptoms of Worsening Heart Failure
RECRUITING · Phase 4
-
Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
RECRUITING · Phase 4
-
Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure
RECRUITING · Phase 4
-
The STOP-MED CTRCD Trial
RECRUITING · Phase 4
-
IRONICA: IRON Repletion In Heart Failure - A Comparison of Oral and IV Approaches
RECRUITING · Phase 4
-
Efficacy Of Sodium Glucose Transporter Inhibitor (SGLT2I) In Adult Patients With Congenital Heart Disease
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI